Platform & Strategies
Publications
HomePlatform & StrategiesPublications
| NO | Pipeline | Journal | Date | Title | Link | |
|---|---|---|---|---|---|---|
| 11 | ABL111 | JITC | 2023 | CLDN18.2 and 4-1BB bispecific antibody givastomig exerts antitumor activity through CLDN18.2-expressing tumor- directed T-cell activation |
|
|
| 10 | General | Vaccines | 2021 | Bispecific Antibodies: A Smart Arsenal for Cancer Immunotherapies |
|
|
| 9 | ADC (Nterm) | mAbs | 2021 | N-terminal selective conjugation method widens the therapeutic window of antibody–drug conjugates by improving tolerability and stability |
|
|
| 8 | ABL503 | JITC | 2021 | Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade |
|
|
| 7 | 4-1BB Platform | Science Advances | 2021 | B7-H3×4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8+tumor-infiltrating lymphocytes |
|
|
| 6 | ABL001 | BMB Reports | 2020 | Synergistic antitumor activity of a DLL4/VEGF bispecific therapeutic antibody in combination with irinotecan in gastric cancer |
|
|
| 5 | ABL001 | Int J Mol Sci | 2020 | ABL001, a bispecific antibody targeting VEGF and DLL4, with chemotherapy, synergistically inhibits tumor progression in xenograft models |
|
|
| 4 | ABL001 | mAbs | 2016 | Simultaneous blockade of VEGF and Dll4 by HD105, a bispecific antibody, inhibits tumor progression and angiogenesis |
|
|
| 3 | General (ABL001) | Mol Cancer Ther. | 2023 | Targeting the DLL/Notch Signaling Pathway in Cancer: Challenges and Advances in Clinical Development |
|
|
| 2 | ABL301 | Cell Rep Methods | 2022 | Grabody B, an IGF1 receptor-based shuttle, mediates efficient delivery of biologics across the blood-brain barrier |
|
|